vs
Side-by-side financial comparison of Amarin Corp plc (AMRN) and HOME BANCORP, INC. (HBCP). Click either name above to swap in a different company.
Amarin Corp plc is the larger business by last-quarter revenue ($45.1M vs $38.2M, roughly 1.2× HOME BANCORP, INC.). HOME BANCORP, INC. runs the higher net margin — 29.7% vs -23.3%, a 53.0% gap on every dollar of revenue. Over the past eight quarters, HOME BANCORP, INC.'s revenue compounded faster (7.4% CAGR vs -18.3%).
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...
AMRN vs HBCP — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $45.1M | $38.2M |
| Net Profit | $-10.5M | $11.4M |
| Gross Margin | — | — |
| Operating Margin | 35.5% | — |
| Net Margin | -23.3% | 29.7% |
| Revenue YoY | 7.0% | — |
| Net Profit YoY | 33.0% | — |
| EPS (diluted) | — | $1.45 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $45.1M | $38.2M | ||
| Q4 25 | $49.2M | $38.0M | ||
| Q3 25 | $49.7M | $37.8M | ||
| Q2 25 | $72.7M | $37.1M | ||
| Q1 25 | $42.0M | $35.8M | ||
| Q4 24 | $62.3M | $35.2M | ||
| Q3 24 | $42.3M | $34.1M | ||
| Q2 24 | $67.5M | $33.1M |
| Q1 26 | $-10.5M | $11.4M | ||
| Q4 25 | $-1.2M | $11.4M | ||
| Q3 25 | $-7.7M | $12.4M | ||
| Q2 25 | $-14.1M | $11.3M | ||
| Q1 25 | $-15.7M | $11.0M | ||
| Q4 24 | $-48.6M | $9.7M | ||
| Q3 24 | $-25.1M | $9.4M | ||
| Q2 24 | $1.5M | $8.1M |
| Q1 26 | — | — | ||
| Q4 25 | 47.1% | — | ||
| Q3 25 | 44.7% | — | ||
| Q2 25 | 69.2% | — | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | -15.4% | — | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 63.4% | — |
| Q1 26 | 35.5% | — | ||
| Q4 25 | -12.9% | 38.2% | ||
| Q3 25 | -22.4% | 41.1% | ||
| Q2 25 | -22.0% | 38.2% | ||
| Q1 25 | -39.9% | 38.6% | ||
| Q4 24 | -84.3% | 34.0% | ||
| Q3 24 | -59.5% | 34.3% | ||
| Q2 24 | -0.8% | 30.4% |
| Q1 26 | -23.3% | 29.7% | ||
| Q4 25 | -2.5% | 30.0% | ||
| Q3 25 | -15.6% | 32.7% | ||
| Q2 25 | -19.4% | 30.6% | ||
| Q1 25 | -37.4% | 30.7% | ||
| Q4 24 | -78.0% | 27.5% | ||
| Q3 24 | -59.4% | 27.7% | ||
| Q2 24 | 2.3% | 24.5% |
| Q1 26 | — | $1.45 | ||
| Q4 25 | $0.00 | $1.46 | ||
| Q3 25 | $-0.02 | $1.59 | ||
| Q2 25 | $-0.03 | $1.45 | ||
| Q1 25 | $-0.04 | $1.37 | ||
| Q4 24 | $-0.12 | $1.21 | ||
| Q3 24 | $-0.06 | $1.18 | ||
| Q2 24 | $0.00 | $1.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $307.8M | $223.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $444.4M |
| Total Assets | $645.8M | $3.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $307.8M | $223.5M | ||
| Q4 25 | $302.6M | — | ||
| Q3 25 | $286.6M | — | ||
| Q2 25 | $298.7M | — | ||
| Q1 25 | $281.8M | — | ||
| Q4 24 | $294.2M | — | ||
| Q3 24 | $305.7M | — | ||
| Q2 24 | $306.7M | — |
| Q1 26 | — | $444.4M | ||
| Q4 25 | $459.3M | $435.1M | ||
| Q3 25 | $458.9M | $423.0M | ||
| Q2 25 | $464.9M | $408.8M | ||
| Q1 25 | $473.7M | $402.8M | ||
| Q4 24 | $486.2M | $396.1M | ||
| Q3 24 | $531.4M | $393.5M | ||
| Q2 24 | $551.9M | $375.8M |
| Q1 26 | $645.8M | $3.6B | ||
| Q4 25 | $670.8M | $3.5B | ||
| Q3 25 | $659.8M | $3.5B | ||
| Q2 25 | $670.1M | $3.5B | ||
| Q1 25 | $655.7M | $3.5B | ||
| Q4 24 | $685.3M | $3.4B | ||
| Q3 24 | $750.6M | $3.4B | ||
| Q2 24 | $799.9M | $3.4B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
HBCP
| Net Interest Income | $34.5M | 90% |
| Noninterest Income | $3.7M | 10% |
